Erin B Bailey

List of Publications by Year
in descending order

128 papers	3,235 citations	147801 31 h-index	182427 51 g-index
129 all docs	129 docs citations	129 times ranked	5327 citing authors

#	Article	IF	Citations
1	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncology, The, 2015, 16, 293-300.	10.7	299
2	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2445-2452.	7.0	193
3	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscleâ€invasive bladder cancer. Cancer, 2015, 121, 2586-2593.	4.1	155
4	Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends in Cancer, 2020, 6, 702-715.	7.4	122
5	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. European Urology, 2017, 72, 557-564.	1.9	108
6	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology, 2021, 18, 313-319.	27.6	103
7	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy, 2017, 9, 681-692.	2.0	94
8	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. European Urology, 2018, 73, 71-78.	1.9	87
9	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 2018, 124, 2115-2124.	4.1	79
10	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2015, 13, e79-e85.	1.9	78
11	Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncology Practice, 2022, 18, 45-55.	2.9	75
12	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
13	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1518-1530.	10.7	69
14	First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2019, 2, 708-715.	5.4	64
15	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. European Urology, 2020, 78, 652-656.	1.9	64
16	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precision Oncology, 2019, 3, 1-23.	3.0	63
17	Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3601-3609.	7.0	58
18	PD-1 checkpoint inhibition: Toxicities and management. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 701-707.	1.6	57

#	Article	IF	Citations
19	Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. Oncologist, 2016, 21, 535-536i.	3.7	54
20	Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer. JAMA Oncology, 2017, 3, 856.	7.1	53
21	Immune Checkpoint Inhibitors in Prostate Cancer. Cancers, 2021, 13, 2187.	3.7	48
22	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Targeted Oncology, 2013, 8, 203-209.	3.6	47
23	Detection and Phenotyping of Circulating Tumor Cells in High-Risk Localized Prostate Cancer. Clinical Genitourinary Cancer, 2015, 13, 130-136.	1.9	45
24	CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 267-275.	3.2	45
25	Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget, 2017, 8, 33614-33620.	1.8	45
26	Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. Annals of Translational Medicine, 2019, 7, S18-S18.	1.7	44
27	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 464-472.	5.4	39
28	Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 365-368.	1.9	38
29	Circulating tumor DNA alterations in patients with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 1459-1469.	4.1	38
30	Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Circulation: Heart Failure, 2018, 11, e004408.	3.9	34
31	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist, 2021, 26, e270-e278.	3.7	33
32	Development of PROSTVAC immunotherapy in prostate cancer. Future Oncology, 2015, 11, 2137-2148.	2.4	31
33	Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Cancer Treatment and Research Communications, 2019, 19, 100116.	1.7	29
34	A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. Oncologist, 2020, 25, 121-e213.	3.7	28
35	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 130-137.	1.9	27
36	Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 363-371.	3.8	27

#	Article	IF	Citations
37	Familial Polycythemia Caused by a Novel Mutation in the Beta Globin Gene: Essential Role of P50 in Evaluation of Familial Polycythemia. International Journal of Medical Sciences, 2007, 4, 232-236.	2.5	26
38	Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. Cancer Treatment and Research Communications, 2021, 27, 100325.	1.7	24
39	Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, 288-292.	1.9	23
40	Taxane-based Combination Therapies for Metastatic Prostate Cancer. European Urology Focus, 2019, 5, 369-380.	3.1	23
41	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. Clinical Genitourinary Cancer, 2020, 18, e543-e556.	1.9	22
42	A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 2021, 21, 510.	2.6	21
43	Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 319-329.	3.8	20
44	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. Cancers, 2021, 13, 4951.	3.7	19
45	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International, 2021, 128, 196-205.	2.5	18
46	Development of Novel Immune Interventions for Prostate Cancer. Clinical Genitourinary Cancer, 2012, 10, 84-92.	1.9	17
47	Correlation of Degree of Hypothyroidism With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2015, 13, e131-e137.	1.9	17
48	Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clinical Genitourinary Cancer, 2017, 15, e599-e602.	1.9	17
49	Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunology, Immunotherapy, 2016, 65, 941-949.	4.2	16
50	Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Current Treatment Options in Oncology, 2019, 20, 14.	3.0	16
51	Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. Research and Reports in Urology, 2018, Volume 10, 205-217.	1.0	15
52	Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma . Cancer Management and Research, 2020, Volume 12, 3741-3749.	1.9	15
53	Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 2104-2110.	7.0	15
54	A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-Î², and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Investigational New Drugs, 2015, 33, 1217-1224.	2.6	14

#	Article	IF	Citations
55	Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clinical Genitourinary Cancer, 2016, 14, 153-159.	1.9	14
56	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal CellÂCarcinoma. Clinical Genitourinary Cancer, 2017, 15, 403-410.e2.	1.9	14
57	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genetics, 2018, 14, e1007679.	3.5	14
58	Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. Journal of Geriatric Oncology, 2019, 10, 149-154.	1.0	14
59	Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 2021, 26, 1006-e2129.	3.7	13
60	Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer. Journal of Urology, 2016, 196, 1112-1116.	0.4	12
61	Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. Oncologist, 2018, 23, 1413-e151.	3.7	11
62	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2â€“4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. European Urology Oncology, 2019, 2, 248-256.	5.4	11
63	Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clinical Genitourinary Cancer, 2020, 18, 274-283.e5.	1.9	11
64	Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. Drugs, 2021, 81, 191-206.	10.9	11
65	Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treatment and Research Communications, 2019, 19, 100120.	1.7	10
66	Finding a niche for girentuximab in metastatic renal cell carcinoma. Nature Reviews Urology, 2016, 13, 442-443.	3.8	9
67	Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 676-677.	1.6	9
68	Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions. European Urology, 2018, 73, 541-542.	1.9	9
69	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clinical Genitourinary Cancer, 2019, 17, 65-71.	1.9	9
70	Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). Molecular Cancer Therapeutics, 2019, 18, 726-729.	4.1	9
71	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 4807-4813.	7.0	9
72	Identification of Somatic Gene Signatures in Circulating <scp>Cell-Free DNA</scp> Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist, 2021, 26, 751-760.	3.7	9

#	Article	IF	Citations
73	The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer Discovery, 2022, 12, 1620-1624.	9.4	9
74	Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS ONE, 2019, 14, e0210415.	2.5	8
75	Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Expert Review of Anticancer Therapy, 2022, 22, 335-341.	2.4	8
76	Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far from the Tree. Clinical Cancer Research, 2017, 23, 6381-6383.	7.0	7
77	Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e169-e172.	1.9	7
78	Immunotherapyâ€based combination strategies for advanced urothelial cancer: A long quest. Cancer, 2020, 126, 4446-4450.	4.1	7
79	Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. JCO Precision Oncology, 2020, 4, 139-151.	3.0	7
80	Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. Journal of Urology, 2021, 205, 709-717.	0.4	7
81	The Role of PD-L1 Testing in Advanced Genitourinary Malignancies. European Urology Focus, 2020, 6, 11-13.	3.1	6
82	Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e573-e584.	1.9	6
83	An Evolving Role for AXL in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 6619-6621.	7.0	6
84	Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Journal of Oncology, 2015, 2015, 1-6.	1.3	5
85	Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?. Lancet Oncology, The, 2019, 20, 1473-1474.	10.7	5
86	Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. Drugs and Aging, 2019, 36, 395-401.	2.7	5
87	Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1097-1105.	2.5	5
88	Management of Hormone-Sensitive Metastatic Prostate Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 1221-1241.	2.2	4
89	Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients With Metastatic Urothelial Carcinoma. Oncologist, 2014, 19, 915-916.	3.7	4
90	Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. European Urology, 2020, 77, 22-23.	1.9	4

#	Article	IF	Citations
91	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical Genitourinary Cancer, 2022, 20, 165-175.	1.9	4
92	A step towards predicting checkpoint inhibitor response in kidney cancer. Lancet Oncology, The, 2017, 18, 982-983.	10.7	3
93	Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. Oncologist, 2019, 24, 143-145.	3.7	3
94	Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer. Cancer Treatment and Research Communications, 2020, 25, 100205.	1.7	3
95	Association of prior local therapy and outcomes with programmedâ€death ligandâ€1 inhibitors in advanced urothelial cancer. BJU International, 2022, 130, 592-603.	2.5	3
96	The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma. Translational Cancer Research, 2019, 8, E1-E6.	1.0	3
97	Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. Lancet Oncology, The, 2016, 17, 1477-1478.	10.7	2
98	Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. Immunotherapy, 2017, 9, 463-466.	2.0	2
99	Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. Journal of Geriatric Oncology, 2020, 11, 724-726.	1.0	2
100	Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics, 2020, 21, 75-81.	1.3	2
101	DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC). World Journal of Oncology, 2018, 9, 119-122.	1.5	2
102	Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 53-59.	1.9	1
103	HSD3B1â€”A Predictive Biomarker in Advanced Prostate Cancer. JAMA Oncology, 2018, 4, 562.	7.1	1
104	Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer. JAMA Oncology, 2020, 6, 225.	7.1	1
105	Quest for Ideal Composite Biomarkers for Response to Immunotherapies. Clinical Cancer Research, 2020, 26, 5059-5061.	7.0	1
106	The HOXB13 p.Gly84Glu variant observed in an extended five generation high-risk prostate cancer pedigree supports risk association for multiple cancer sites. Cancer Epidemiology, 2020, 69, 101834.	1.9	1
107	Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. Oncologist, 2020, 25, 186-188.	3.7	1
108	Quantifying the Costs of Care Among Patients With High-Risk Nonâ€“Muscle-Invasive Bladder Cancer Treated in the Veterans Health Administration. JAMA Network Open, 2021, 4, e213816.	5.9	1

#	Article	IF	Citations
109	Urologists, Youâ€™ll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Nonâ€“muscle-invasive Bladder Cancer. European Urology Oncology, 2022, 5, 268-272.	5.4	1
110	Editorial Comment. Journal of Urology, 2021, 206, 1429-1429.	0.4	1
111	Successful Recruitment of Black Men to Prostate Cancer Clinical Trialsâ€”A Lesson in Achievement. JAMA Network Open, 2021, 4, e2034652.	5.9	1
112	Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report. Cancer Treatment and Research Communications, 2021, 29, 100480.	1.7	1
113	Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations. American Journal of Translational Research (discontinued), 2021, 13, 7427-7439.	0.0	1
114	Circulating tumor cells in prostate cancer: Does (nuclear) size matter?. Cancer, 2015, 121, 3190-3192.	4.1	0
115	Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naive Patients With Metastatic Renal Cell Carcinoma. JAMA Oncology, 2016, 2, 1273.	7.1	0
116	Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. European Urology, 2016, 70, 42-44.	1.9	0
117	Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma?. European Urology, 2017, 72, 972-973.	1.9	0
118	Ideal Glucocorticoid Regimen With Abiraterone Acetate. JAMA Oncology, 2019, 5, 1167.	7.1	0
119	Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 352.e19-352.e24.	1.6	0
120	The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatinâ€Ineligible Patients with Muscleâ€Invasive Localized Urothelial Carcinoma. Oncologist, 2019, 24, 580-583.	3.7	0
121	The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas. Cancer Treatment and Research Communications, 2020, 24, 100190.	1.7	0
122	Reply to Salma Kaochar, Nicholas Mitsiadesâ€™ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652â€“6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?. European Urology, 2021, 79, e94-e95.	1.9	0
123	Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. European Urology Oncology, 2021, 4, 553-557.	5.4	0
124	A Novel Mutation of the Î± Spectrin Gene in a Family of Northern European Descent Is Associated with Three Different Phenotypes.. Blood, 2007, 110, 1717-1717.	1.4	0
125	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2012, 30, 308-308.	1.6	0
126	Integrating Emerging Science into Clinical Practice: Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer. , 2014, , 99-113.		0

#	Article	IF	Citations
127	Optimal treatment in the postorchiectomy management of clinical stage I seminoma. Oncology, 2009, 23, 764, 767.	0.5	0
128	Black Men Receiving Radiotherapy for Localized Prostate Cancer Have Improved Outcomesâ€"Clinical Trial Access or Racial Advantage?. JAMA Network Open, 2021, 4, e2140692.	5.9	0